Physician profile
Atul Kumar
NPI 1316049257
$21,978.19
in general payments reported to CMS, 2019-2025
15 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10K · 2022: $372 · 2023: $499 · 2024: $11K · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,260.00 |
| Food and Beverage | $1,260.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Bioscience INC. | $10,260.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10,200.00 | 2021-2022 | |
| Abbvie INC. | $266.15 | 2023-2024 | |
| Endogastric Solutions, INC | $265.97 | 2023-2024 | Esophyx |
| E.R. Squibb & Sons, L.L.C. | $224.40 | 2022 | |
| Boston Scientific Corporation | $209.91 | 2021-2025 | General - Biliary Devices, Exalt Model D |
| Madrigal Pharmaceuticals | $140.44 | 2024 | Rezdiffra |
| Genzyme Corporation | $122.92 | 2023 | |
| Medtronic, INC. | $86.43 | 2024 | Barrx |
| Apollo Endosurgery US INC | $72.75 | 2023 | Overstitch Endoscopic Suturing System |
| Janssen Biotech, INC. | $59.37 | 2022-2023 | Stelara, Simponi, Simponi Aria |
| Ferring Pharmaceuticals INC. | $26.18 | 2024 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.43 | 2023 | Xifaxan |
| Olympus Corporation of The Americas | $21.24 | 2023 | Visiglide |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.